Advertisement

Verminderung der zytostatikaassoziierten Toxizität bei älteren Patienten

  • C. Bokemeyer
  • H.-P. Lipp
Chapter
  • 27 Downloads

Zusammenfassung

Zytostatika zählen zu den Wirkstoffen mit geringer therapeutischer Breite. Ist ihre hepatische, metabolische oder renale Clearance vermindert, so kann es zu einer gefährlichen Kumulation der antineoplastisch wirksamen Verbindungen im Gesamtorganismus kommen. Problematisch wird diese Situation, wenn Organe, die besonders empfindlich auf höhere Zytostatikakonzentrationen reagieren, bereits Vorschädigungen aufweisen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur zu 12

  1. Cascinu S, Del-Ferro E, Catalano G (1996) Toxicity and therapeutic response to chemotherapy in patients aged 70 years or older with advanced cancer. Am J Clin Oncol 19: 371–374PubMedCrossRefGoogle Scholar
  2. Dajczman E, Fu LY, Small D, Wolkove N, Kreisman H (1996) Treatment of small cell lung carcinoma in the elderly. Cancer 77: 2032–2038PubMedCrossRefGoogle Scholar
  3. Guerci A, Lederlin P, Reyes F et al. on behalf of the Groupe d’Etudes des Lymphomes de l’Adulte (1996) Effect of granulocyte colony-stimulating factor administration in elderly patients with aggressive non-Hodgkin’s lymphoma treated with a pirarubicin-combination chemotherapy regimen. Ann Oncol 7: 966–969PubMedGoogle Scholar
  4. Ibrahim NK, Frye DK, Buzdar AU, Walters RS, Hortobagyi GN (1996) Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome. Arch Intern Med 156: 882–888PubMedCrossRefGoogle Scholar
  5. Kintzel PE, Dorr RT (1995) Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev 21: 33–64PubMedCrossRefGoogle Scholar
  6. Lichtman SM (1995) Physiological aspects of aging. Implications for the treatment of cancer. Drugs Aging 7: 212–225PubMedCrossRefGoogle Scholar
  7. Lipp HP, Bokemeyer C (1997) Individuelle Carboplatindosierung. Arzneimitteltherapie 15: 42–48Google Scholar
  8. Maslak PG, Weiss MA, Berman E et al. (1996) Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemia. Leukemia 10: 32–39PubMedGoogle Scholar
  9. Nou-E (1996) Full chemotherapy in elderly patients with small cell bronchial carcinoma. Acta Oncol 35: 399–406PubMedCrossRefGoogle Scholar
  10. Oshita F, Kurata T, Kasai T et al. (1995) Prospective evaluation of the feasibility of cisplatin-based chemotherapy for elderly lung cancer patients with normal organ functions. Jpn J Cancer Res 86: 1198–1202PubMedCrossRefGoogle Scholar
  11. Rossini F (1996) Prognosis of infections in elderly patients with haematological diseases. Support Care Cancer 4: 46–50PubMedCrossRefGoogle Scholar
  12. Sonneveld P, Ridder M de, Lelie H van der et al. (1995) Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin’s lymphoma using CHOP vs. CNOP chemotherapy. J Clin Oncol 13: 2530–2539PubMedGoogle Scholar
  13. Stasi R, Venditti A, Del-Poeta G et al. (1996) Intensive treatment of patients age 60 years and older with de novo acute myeloid leukemia: analysis of prognostic factors. Cancer 77: 2476–2488PubMedCrossRefGoogle Scholar
  14. Tonato M, Mosconi AM, Martin C (1995) Safety profile of gemcitabine. Anticancer Drugs 6 (Suppl 6): 27–32PubMedCrossRefGoogle Scholar
  15. Zagonel V, Fratino L, Sacco C et al. (1996) Reducing chemotherapy-associated toxicity in elderly cancer patients. Cancer Treat Rev 22: 223–244PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • C. Bokemeyer
  • H.-P. Lipp

There are no affiliations available

Personalised recommendations